Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 501–600 of 1,000
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Caster, J. M., Callaghan, C. M., Seyedin, S. N., Henderson, K., Sun, B., & Wang, A. Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.009 · Cited by 56
Seyedin, S. N., Hasibuzzaman, M. M., Pham, V., Petronek, M. S., Callaghan, C. M., Kalen, A. L., Mapuskar, K. A., Mott, S. L., Spitz, D. R., Allen, B. G., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.030 · Cited by 56
Ohno, A., Iwata, T., Katoh, Y., Taniguchi, S., Tanaka, K., Nishio, H., Nakamura, M., Morisada, T., Chen, G., Saito, M., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.106 · Cited by 56
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
Limited, O. B. O. A. U., & Conibear, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01070-6 · Cited by 56
Playing hide and seek: Tumor cells in control of MHC class I antigen presentation
Jongsma, M. L. M., Neefjes, J., & Spaapen, R. M. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.05.009 · Cited by 56
Self-citationEnhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 56
IFN-λ Enhances Constitutive Expression of MHC Class I Molecules on Thymic Epithelial Cells
Benhammadi, M., Mathé, J., Dumont-Lagacé, M., Kobayashi, K. S., Gaboury, L. A., Brochu, S., & Perreault, C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000225 · Cited by 55
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 56
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors
Neagu, M. R., & Reardon, D. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0371-3 · Cited by 55
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 55
Tumour radiosensitivity is associated with immune activation in solid tumours
Ström, T., Harrison, L. B., Giuliano, A. R., Schell, M. J., Eschrich, S. A., Berglund, A., Fulp, W. J., Thapa, R., Coppola, D., Kim, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.001 · Cited by 55
Lee, H. J., Zeng, J., & Rengan, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.28 · Cited by 56
The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment
Weichselbaum, R. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00847 · Cited by 55
Radiotherapy in Combination With Cytokine Treatment
Palata, O., Podzimkova, N., Nedvedova, E., Umprecht, A., Sadilkova, L. K., Jelinkova, L. P., Špíšek, R., & Adkins, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00367 · Cited by 55
Zeng, H., Zhang, W., Gong, Y. Q., & Xie, C. (2019) · Journal of International Medical Research · doi:10.1177/0300060519855595 · Cited by 55
Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy
Regen-Tuero, H. C., Ward, R. C., Sikov, W. M., & Littrup, P. J. (2021) · Radiology Imaging Cancer · doi:10.1148/rycan.2021200134 · Cited by 55
The abscopal effect: a sense of DNA damage is in the air
Lippert, T. P., & Greenberg, R. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148274 · Cited by 55
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Gafita, A., Marcus, C. V., Kostos, L. K., Schuster, D. M., Calais, J., & Hofman, M. S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350946 · Cited by 55
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 55
Combination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 54
Immunotherapy for Medulloblastoma: Current Perspectives
Kabir, T., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s198162 · Cited by 54
Immuno-regulatory antibodies for the treatment of cancer
Honeychurch, J., Cheadle, E. J., Dovedi, S. J., & Illidge, T. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036737 · Cited by 53
Jin, W. J., Zangl, L. M., Hyun, M., Massoud, E., Schroeder, K., Alexandridis, R. A., & Morris, Z. S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007474 · Cited by 53
Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses
Gamrekelashvili, J., Krüger, C., von Wasielewski, R., Hoffmann, M., Huster, K. M., Busch, D. H., Manns, M. P., Korangy, F., & Greten, T. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1573 · Cited by 53
Accolla, R. S., Lombardo, L., Abdallah, R., Raval, G., Forlani, G., & Tosi, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00032 · Cited by 53
Hald, S. M., Bremnes, R. M., Al-Shibli, K. I., Al‐Saad, S., Andersen, S., Stenvold, H., Busund, L., & Dønnem, T. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.026 · Cited by 53
Adapting conventional cancer treatment for immunotherapy
Qiao, J., Liu, Z., & Fu, Y. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1393-4 · Cited by 53
Recent developments in cancer therapy and diagnosis
Gündoğdu, E., İlem‐Özdemir, D., Ekinci, M., Özgenç, E., Demir, E. S., Sánchez-Dengra, B., & González‐Álvarez, I. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00473-0 · Cited by 53
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49
Radiotherapy and the Tumor Microenvironment: Mutual Influence and Clinical Implications
Thompson, R. F., & Maity, A. M. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_7 · Cited by 53
Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44195-x · Cited by 52
Kroon, P., Frijlink, E., Iglesias‐Guimarais, V., Volkov, A., van Buuren, M. M., Schumacher, T. N., Verheij, M., Borst, J. G., & Verbrugge, I. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0654 · Cited by 52
Li, Z., Wang, K., Shi, Y., Zhang, X., & Wen, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32259 · Cited by 52
The role of radiotherapy in the age of immunotherapy
Sato, H., Demaria, S., & Ohno, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa268 · Cited by 52
NHS-IL12, a Tumor-Targeting Immunocytokine
Greiner, J. W., Morillon, Y. M., & Schlom, J. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306150 · Cited by 52
Self-citationHuang, Y., Sheng, H., Xiao, Y., Hu, W., Zhang, Z., Chen, Y., Zhu, Z., Wu, D., Cao, C., & Sun, J. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.034 · Cited by 52
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Manjunath, S. H., Cohen, A. D., Lacey, S. F., Suhoski, M. M., Garfall, A. L., Melenhorst, J. J., Maxwell, R., Arscott, W. T., Maity, A. M., Jones, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0308 · Cited by 52
Redirecting T lymphocyte specificity by T cell receptor gene transfer – A new era for immunotherapy
Engels, B., & Uckert, W. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.006 · Cited by 52
Oyoshi, H., Du, J., Sakai, S. A., Yamashita, R., Okumura, M., Motegi, A., Hojo, H., Nakamura, M., Hirata, H., Sunakawa, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9069 · Cited by 51
Immune checkpoint inhibitors in small cell lung cancer
Pakkala, S., & Owonikoko, T. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.51 · Cited by 51
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 51
Theelen, W. S. M. E., de Jong, M. C., & Baas, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.015 · Cited by 51
Oba, T., Makino, K., Kajihara, R., Yokoi, T., Araki, R., Abe, M., Minderman, H., Chang, A. E., Odunsi, K. O., & Ito, F. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002432 · Cited by 51
Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
Boustani, J., Lecoester, B., Baude, J., Latour, C., Adotévi, O., Mirjolet, C., & Truc, G. (2021) · Cancers · doi:10.3390/cancers13194893 · Cited by 51
Cai, M., Fu, T., Zhu, R., Hu, P., Kong, J., Liao, S., Du, Y., Zhang, Y., Qu, C., Dong, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.015 · Cited by 50
Interferon signaling pathways in health and disease
Wen, C., Lan, Q., Wang, Y., Ni, Y., Wong, A. S. T., & Liu, D. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00381-5 · Cited by 51
Immunomodulatory Effects of Radiation: What is Next for Cancer Therapy?
Kumari, A., Simon, S., Moody, T. D., & Garnett‐Benson, C. (2015) · Future Oncology · doi:10.2217/fon.15.300 · Cited by 50
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
Brooks, E. D., Schoenhals, J. E., Tang, C. Z., Micevic, G., Gomez, D. R., Chang, J. Y., & Welsh, J. W. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000210 · Cited by 52
Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Ji, D., Yi, H., Zhang, D., Zhan, T., Li, Z., Li, M., Jia, J., Qiao, M., Xia, J., Zhai, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0630 · Cited by 50
Domankevich, V., Cohen, A., Efrati, M., Schmidt, M. T., Rammensee, H., Nair, S. S., Tewari, A. K., Kelson, I., & Keisari, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02418-5 · Cited by 50
Curti, B. D., Crittenden, M. R., Seung, S. K., Fountain, C. B., Payne, R., Chang, S., Fleser, J., Phillips, K. S., Malkasian, I., Dobrunick, L. B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000773 · Cited by 50
Hormuth, D. A., Farhat, M., Christenson, C., Curl, B. J., Quarles, C. C., Chung, C. D., & Yankeelov, T. E. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114367 · Cited by 50
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 50
van der Woude, L. L., Gorris, M. A. J., Wortel, I. M. N., Creemers, J. H. A., Verrijp, K. N., Monkhorst, K., Grünberg, K., van den Heuvel, M. M., Textor, J. C., Figdor, C. G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005248 · Cited by 49
Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy
Wang, X., Zhang, H., XinZhang, & Liu, Y. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00628-3 · Cited by 49
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
Cai, M., Wang, Y., Ma, H., Li, Y., & Xu, Z. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102840 · Cited by 49
Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J. D., Enderling, H., Schoenfeld, J. D., Brody, J., McGee, H. M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00656-9 · Cited by 49
Modification of the tumor microenvironment to enhance immunity
Liao, Y., Schaue, D., & McBride, W. H. (2007) · Frontiers in bioscience · doi:10.2741/2336 · Cited by 49
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Fritzell, S., Sandén, E., Eberstål, S., Visse, E., Darabi, A., & Siesjö, P. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1449-z · Cited by 49
Combining stereotactic body radiation therapy with immunotherapy: current data and future directions
Lin, A. J., Roach, M. C., Bradley, J. D., & Robinson, C. G. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.16 · Cited by 49
Tang, C. Z., Lee, W.-C., Reuben, A., Chang, L., Tran, H. T., Little, L., Gumbs, C. E., Wargo, J. A., Futreal, P. A., Liao, Z. X., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.10.038 · Cited by 49
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 49
Radiation and immunotherapy: emerging mechanisms of synergy
Breen, W. G., Leventakos, K., Dong, H., & Merrell, K. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-cptn-07 · Cited by 49
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 49
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 49
Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects
Jiang, Y., Wang, C., Zu, C., Rong, X., Yu, Q., & Jiang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s466396 · Cited by 48
Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group
Elsayad, K., Guenova, E., Assaf, C., Nicolay, J. P., Trautinger, F., Stadler, R., Waldstein, C., Boterberg, T., Meijnders, P. J., Kirova, Y., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115064 · Cited by 48
Heinzerling, J. H., Mileham, K. F., Robinson, M. M., Symanowski, J. T., Induru, R. R., Brouse, G., Corso, C. D., Prabhu, R. S., Haggstrom, D. E., Moeller, B. J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00573-4 · Cited by 48
Schoenhals, J. E., Seyedin, S. N., Tang, C. Z., Cortez, M. A., Niknam, S., Tsouko, E., Chang, J. Y., Hahn, S. M., & Welsh, J. W. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000181 · Cited by 48
Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature
Sindoni, A., Minutoli, F., Ascenti, G., & Pergolizzi, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.003 · Cited by 48
Patel, P., Sun, L., Robbins, Y. L., Clavijo, P. E., Friedman, J., Silvin, C. J., Waes, C. V., Cook, J. A., Mitchell, J. B., & Allen, C. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638207 · Cited by 48
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
de Jong, F. C., Rutten, V. C., Zuiverloon, T. C. M., & Theodorescu, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062800 · Cited by 48
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 48
Ganem, G., Cartron, G., Girinsky, T., Haas, R. L., Cosset, J. M., & Solal‐Céligny, P. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.056 · Cited by 48
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
Bellavia, M. C., Patel, R. B., & Anderson, C. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264373 · Cited by 47
Chargari, C., Clemenson, C., Martins, I., Perfettini, J.-L., & Deutsch, E. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.01.001 · Cited by 39
Bessout, R., Sémont, A., Demarquay, C., Charcosset, A., Benderitter, M., & Mathieu, N. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.85 · Cited by 47
Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
Draghiciu, O., Walczak, M., Hoogeboom, B. N., Franken, K. L. M. C., Melief, K., Nijman, H. W., & Daemen, T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28418 · Cited by 47
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Guo, Y., Wang, Y., & Han, W. (2016) · Journal of Immunology Research · doi:10.1155/2016/3850839 · Cited by 45
Therapeutic vaccination strategies to treat nasopharyngeal carcinoma
Taylor, G. S., & Steven, N. M. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.03.20 · Cited by 47
Attili, I., Passaro, A., Pavan, A., Conte, P., de Marinis, F., & Bonanno, L. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.007 · Cited by 47
Chang, M., Chen, Y., Lin, H.-W., Chiang, Y., Chang, C.-F., Hsieh, S., Chen, C., Sun, W., & Cheng, W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.011 · Cited by 47
Murphy, B. M., Walker, J. M., Bassale, S., Monaco, D., Jaboin, J. J., Ciporen, J. N., Taylor, M., & Kubicky, C. D. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000509 · Cited by 47
Wang, C., Park, J., Ouyang, C., Longmate, J., Tajon, M., Chao, J., Lim, D. W., Sandhu, J. S., Yin, H. H., Pillai, R. K., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0924 · Cited by 47
The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches
Tubin, S., Yan, W., Mourad, W. F., Fossati, P., & Khan, M. K. (2020) · Future Oncology · doi:10.2217/fon-2020-0063 · Cited by 47
Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review
Takahashi, J., & Nagasawa, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239324 · Cited by 48
Complement in Tumourigenesis and the Response to Cancer Therapy
O'Brien, R. M., Cannon, A., Reynolds, J. V., Lysaght, J., & Lynam‐Lennon, N. (2021) · Cancers · doi:10.3390/cancers13061209 · Cited by 48
Janssen, Q. P., van Dam, J. L., Kivits, I. G., Besselink, M. G., van Eijck, C. H. J., Homs, M. Y. V., Nuyttens, J. J. M. E., Qi, H., van Santvoort, H. C., Wei, A. C.-C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10276-8 · Cited by 47
Nenclares, P., Rullan, A., Tam, K., Dunn, L. A., John, M. A. S., & Harrington, K. J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351336 · Cited by 47
Application of injectable hydrogels in cancer immunotherapy
Liu, C., Liao, Y., Liu, L., Xie, L., Liu, J., Zhang, Y., & Li, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1121887 · Cited by 48
Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner
Hosseinalizadeh, H., Wang, L.-S., Mirzaei, H., Amoozgar, Z., Tian, L., & Yu, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.057 · Cited by 46
Crittenden, M. R., Savage, T., Cottam, B., Bahjat, K. S., Redmond, W. L., Bambina, S., Kasiewicz, M. J., Newell, P., Jackson, A. M., & Gough, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069527 · Cited by 46
Gasser, S., Zhang, W. Y. L., Tan, N. Y., Tripathi, S., Suter, M. A., Chew, Z. H., Khatoo, M., Ngeow, J. Y. Y., & Cheung, F. S. G. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.001 · Cited by 46
Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review
Plazy, C., Hannani, D., & Gobbini, É. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01241-z · Cited by 46
Hu, Y. Y., Paris, S., Bertolet, G., Barsoumian, H. B., He, K., Sezen, D., Chen, D., Wasley, M. D., SILVA, J. D., Mitchell, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01621-4 · Cited by 46
Avogadri, F., Mittal, D., Saccheri, F., Fiore, M. S., Ciocca, M., Larghi, P., Orecchia, R., & Rescigno, M. (2008) · European Journal of Immunology · doi:10.1002/eji.200738035 · Cited by 46
mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
Fotin-Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Kowalczyk, A., Kallen, K.-J., & Huber, S. M. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-180 · Cited by 44
Melenhorst, J. J., Tian, X., Xu, D., Utay, N. S., Scheinberg, P., Biancotto, A., Scheinberg, P., McCoy, J. P., Hensel, N. F., McIver, Z. A., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.053363 · Cited by 46
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.